ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Lowered by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. trimmed its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 232,250 shares of the biotechnology company’s stock after selling 16,227 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in ADMA Biologics were worth $1,050,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Stephens Consulting LLC acquired a new position in ADMA Biologics during the third quarter valued at $36,000. Cerity Partners LLC acquired a new position in ADMA Biologics during the second quarter valued at $37,000. Envestnet Asset Management Inc. acquired a new position in ADMA Biologics during the first quarter valued at $35,000. GTS Securities LLC acquired a new position in ADMA Biologics during the third quarter valued at $38,000. Finally, Arkadios Wealth Advisors acquired a new position in ADMA Biologics during the third quarter valued at $40,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 183,008 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $6.01, for a total transaction of $1,099,878.08. Following the completion of the sale, the director now owns 2,577,387 shares in the company, valued at approximately $15,490,095.87. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 639,895 shares of company stock worth $3,927,169. 6.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ADMA has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Cantor Fitzgerald upped their target price on ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Finally, Mizuho upped their target price on ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $7.88.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $6.02 on Monday. The firm has a market cap of $1.37 billion, a P/E ratio of -46.31 and a beta of 0.46. The stock’s 50-day moving average is $5.86 and its two-hundred day moving average is $4.68. ADMA Biologics, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $6.76. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $73.90 million during the quarter, compared to the consensus estimate of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. Analysts predict that ADMA Biologics, Inc. will post 0.3 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.